BCAL Launches Next-Gen Breast Cancer Test
Key points
- BREASTESTplus 2 validated for women 30+ and all breast densities
- Sensitivity of 80.3% and specificity of 48.5% in clinical validation
- Launch planned for November 2026 in Sydney, Melbourne, and Brisbane
Full summary
BCAL Diagnostics Limited, an Australian healthcare company, has completed the clinical validation of its next-generation BREASTESTplus 2 blood test for early-stage breast cancer detection across all breast densities. The test demonstrated a sensitivity of 80.3% and specificity of 48.5% in the validation study, supporting its clinical use. BREASTESTplus 2 is applicable for women aged 30 and above, broadening the population who can access the test. The commercial launch is scheduled for November 2026, starting in Sydney, Melbourne, and Brisbane, followed by a national rollout. The test is designed to provide additional information to support clinical decision-making and is not intended as a standalone diagnostic tool.
Summary generated by a large language model. Please interpret with care.